Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR


Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 8 8 2023
pubmed: 7 8 2023
entrez: 7 8 2023
Statut: ppublish

Résumé

Hexahydroquinoline (HHQ) scaffold was constructed and recruited for development of new series of anticancer agents. Thirty-two new compounds were synthesised where x-ray crystallography was performed to confirm enantiomerism. Thirteen compounds showed moderate to good activity against NCI 60 cancer cell lines, with GI % mean up to 74% for New 32 hexahydroquinoline (HHQ) analogues

Autres résumés

Type: plain-language-summary (eng)
New 32 hexahydroquinoline (HHQ) analogues

Identifiants

pubmed: 37548154
doi: 10.1080/14756366.2023.2241674
pmc: PMC10408569
doi:

Substances chimiques

Antineoplastic Agents 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Erlotinib Hydrochloride DA87705X9K
Protein Kinase Inhibitors 0
Quinolines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2241674

Références

Cancer Discov. 2022 Jan;12(1):74-89
pubmed: 34548309
J Med Chem. 2021 Mar 25;64(6):2878-2900
pubmed: 33719439
Nat Cancer. 2022 Apr;3(4):402-417
pubmed: 35422503
BJU Int. 2018 Mar;121(3):348-356
pubmed: 28921872
Bioorg Chem. 2022 Oct;127:105995
pubmed: 35792315
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2644-2659
pubmed: 36146940
ACS Omega. 2023 Feb 17;8(8):7666-7683
pubmed: 36872984
J Mol Graph Model. 2022 May;112:108114
pubmed: 34979367
J Org Chem. 2019 Feb 1;84(3):1139-1153
pubmed: 30648858
Bioorg Med Chem Lett. 2023 Jan 15;80:129104
pubmed: 36509365
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2489-2511
pubmed: 36093880
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2199166
pubmed: 37038884
J Enzyme Inhib Med Chem. 2013 Feb;28(1):123-30
pubmed: 22136527
Curr Treat Options Oncol. 2020 Feb 3;21(1):9
pubmed: 32016630
Arch Pharm (Weinheim). 2023 Jan;356(1):e2200417
pubmed: 36257809
Cancer Lett. 2020 Jan 28;469:207-216
pubmed: 31639425
Int J Mol Sci. 2019 Jan 03;20(1):
pubmed: 30609789
Front Chem. 2022 Sep 21;10:1008568
pubmed: 36212061
Lung Cancer. 2023 Apr;178:237-246
pubmed: 36907051
Sci Rep. 2022 Aug 26;12(1):14624
pubmed: 36028744
Eur J Med Chem. 2022 Mar 15;232:114190
pubmed: 35182815
Am J Cancer Res. 2019 Oct 01;9(10):2103-2119
pubmed: 31720077
Bioorg Chem. 2020 Dec;105:104274
pubmed: 33339080
J Biomol Struct Dyn. 2022 Dec 28;:1-10
pubmed: 36576127
Bioorg Chem. 2017 Dec;75:368-392
pubmed: 29096097
Bioorg Chem. 2022 Jun;123:105770
pubmed: 35395446
Sci Rep. 2022 Jul 27;12(1):12821
pubmed: 35896557
Pharmacol Res. 2019 Jan;139:395-411
pubmed: 30500458
Drug Resist Updat. 2022 Mar;61:100821
pubmed: 35219075
Chem Biol Drug Des. 2022 Dec;100(6):921-934
pubmed: 34651438
Pharmacol Res. 2021 May;167:105583
pubmed: 33775864
Eur J Med Chem. 2023 May 5;251:115254
pubmed: 36893627
Front Pharmacol. 2018 Oct 09;9:1097
pubmed: 30356705
Nat Commun. 2022 May 9;13(1):2530
pubmed: 35534503
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Cancer. 2022 Feb 15;150(4):626-635
pubmed: 34558665
Acta Crystallogr E Crystallogr Commun. 2018 Oct 12;74(Pt 11):1577-1579
pubmed: 30443384
Eur J Med Chem. 2019 Feb 15;164:317-333
pubmed: 30605830
Chem Biol Drug Des. 2022 Apr;99(4):547-560
pubmed: 34873844
Antioxidants (Basel). 2019 Jul 07;8(7):
pubmed: 31284642
J Biomol Struct Dyn. 2022 Apr;40(7):3046-3059
pubmed: 33174519
Mol Divers. 2022 Dec 31;:
pubmed: 36585569
Eur J Med Chem. 2014 Apr 9;76:549-57
pubmed: 24607998
Mol Divers. 2023 Feb 15;:
pubmed: 36790582
Eur J Med Chem. 2015 Apr 13;94:175-94
pubmed: 25768701
Appl Biochem Biotechnol. 2022 Oct;194(10):4292-4318
pubmed: 35366187
Molecules. 2021 Dec 17;26(24):
pubmed: 34946735
Bioorg Chem. 2022 Oct;127:106006
pubmed: 35820328
J Thorac Dis. 2020 May;12(5):2851-2858
pubmed: 32642198
Bioorg Med Chem. 2019 Dec 1;27(23):115126
pubmed: 31648875
Expert Opin Pharmacother. 2022 Apr;23(6):647-652
pubmed: 35272542
J Enzyme Inhib Med Chem. 2023 Dec;38(1):118-137
pubmed: 36305290
Medicine (Baltimore). 2023 Feb 10;102(6):e31318
pubmed: 36820539
Cancer Res. 2018 Sep 1;78(17):4984-4996
pubmed: 29945960
Mol Divers. 2019 May;23(2):471-508
pubmed: 30390186
J Biomol Struct Dyn. 2023 Aug-Sep;41(13):6134-6144
pubmed: 35903965
J Biomol Struct Dyn. 2023 Aug-Sep;41(14):6492-6501
pubmed: 35968630
Cancer Res. 2019 Feb 15;79(4):689-698
pubmed: 30718357
Mol Pharm. 2022 Feb 7;19(2):661-673
pubmed: 35040326
Arch Pharm (Weinheim). 2021 Aug 31;:e2100258
pubmed: 34467546
Bioorg Chem. 2023 Feb;131:106310
pubmed: 36528923
J Biomol Struct Dyn. 2023 Jan 25;:1-14
pubmed: 36695102
Bioorg Chem. 2022 Dec;129:106172
pubmed: 36182865
Bioorg Chem. 2022 Sep;126:105918
pubmed: 35696765
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514
pubmed: 35534623
J Sci Food Agric. 2023 Feb;103(3):1474-1483
pubmed: 36168817
J Biomol Struct Dyn. 2023 Oct-Nov;41(18):8876-8890
pubmed: 36310097
Lancet Respir Med. 2022 Jan;10(1):72-82
pubmed: 34454653
J Med Chem. 2022 Dec 8;65(23):15540-15558
pubmed: 36395392
Int J Mol Sci. 2023 Jan 31;24(3):
pubmed: 36768973
Bioorg Chem. 2023 May;134:106444
pubmed: 36893547
Arch Pharm (Weinheim). 2010 Sep;343(9):519-27
pubmed: 20814944
Molecules. 2022 Jan 21;27(3):
pubmed: 35163957
Eur J Med Chem. 2023 Jan 5;245(Pt 1):114889
pubmed: 36375337
Bioorg Chem. 2023 Feb;131:106299
pubmed: 36493622
Bioorg Med Chem Lett. 2022 Jul 1;67:128703
pubmed: 35364239
Eur J Med Chem. 2011 Jan;46(1):201-7
pubmed: 21112675
Melanoma Res. 2018 Dec;28(6):536-546
pubmed: 30124539
Curr Top Med Chem. 2020;20(10):815-834
pubmed: 32124699
Life (Basel). 2023 Jan 09;13(1):
pubmed: 36676140
Eur J Med Chem. 2019 May 1;169:121-143
pubmed: 30875504
J Mol Model. 2013 Feb;19(2):497-509
pubmed: 22955422
ACS Omega. 2022 Dec 03;7(49):45535-45544
pubmed: 36530244
J Enzyme Inhib Med Chem. 2019 Dec;34(1):838-852
pubmed: 30919701
Cancer Cell. 2007 Mar;11(3):217-27
pubmed: 17349580
Chem Rev. 2015 Oct 14;115(19):10530-74
pubmed: 26313138
Eur J Med Chem. 2022 Sep 5;239:114542
pubmed: 35751979
Org Biomol Chem. 2020 Oct 7;18(38):7608-7634
pubmed: 32959865
Nat Commun. 2021 Dec 1;12(1):7005
pubmed: 34853305
Bioorg Chem. 2023 Feb;131:106304
pubmed: 36463590
J Biomol Struct Dyn. 2023 Jan 20;:1-15
pubmed: 36661285
Drug Des Devel Ther. 2022 May 16;16:1457-1471
pubmed: 35607598
Comput Biol Med. 2022 Aug;147:105787
pubmed: 35803080
Carbohydr Polym. 2019 Jan 15;204:131-141
pubmed: 30366524
Lung Cancer. 2019 Nov;137:113-122
pubmed: 31568888
Bioorg Chem. 2023 Feb;131:106309
pubmed: 36502567
ACS Appl Mater Interfaces. 2022 Apr 6;14(13):14928-14943
pubmed: 35319877
J Thorac Dis. 2018 Apr;10(4):2311-2320
pubmed: 29850136

Auteurs

Mahmoud G Abo Al-Hamd (MG)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Haytham O Tawfik (HO)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Omeima Abdullah (O)

Pharmaceutical Chemistry Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.

Koki Yamaguchi (K)

Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.

Masaharu Sugiura (M)

Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.

Ahmed B M Mehany (ABM)

Zoology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.

Mervat H El-Hamamsy (MH)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Tarek F El-Moselhy (TF)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH